New treatment strategies based on apoptosis and viruses;Nuevas estrategias terapéuticas basadas en apoptosis y virus

Acta Bioquimica Clinica Latinoamericana

Volumn 37, Issue 1, 2003, Pages 13-19

  Mersich, Susana ^a   Gadaleta, Patricia ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Apoptosis; Human diseases; Mitochondria; Treatments; Virus

Indexed keywords

CASPASE; FAS ANTIGEN; OLIGONUCLEOTIDE; ONYX 015; PROTEIN BCL 2; PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; HOMEOSTASIS; LYMPHOMA; MAMMAL CELL; MITOCHONDRION; MOLECULAR DYNAMICS; NEUROTROPISM; NONHUMAN; PATHOLOGY; VIRUS;

MAMMALIA;

EID: 0038298207     PISSN: 03252957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
2. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-36.
3. Gottlieb RA. Mitochondria and apoptosis. Biol Signals Recept 2001; 10: 147-61.
4. Reed JC. Mechanism of apoptosis. Am J Pathol 2000; 157: 1415-30.
5. Korsmeyer SJ, Wei MC, Saito M, Weiter KJO, Sclessinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73.
6. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
7. Puthalakath H, Huang DC, O'Reilly LA, Kung SM, Strasser A. The proapoptotic activity of Bcl-2 family member Bim is regulated by interaction with the dyneim motor complex. Mol Cell 1999; 3: 287-96.
8. Gross A, Mc Donnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
9. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. Bid-defficient mice resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-91.
10. Reed JC, Tomaselli KJ. Drug discovery opportunities from apoptosis research. Curr Opin Biotechnol 2000; 11: 586-92.
11. Jackson AC. Apoptotic cell death in experimental rabies in suckling mice. Acta Neuropathol 1997; 95: 159-64.
12. Allsopp TE, Scallan MF, Willims A, Fazakerley JK. Virus infection induces neuronal apoptosis. A comparison with trophic factor withdrawal. Cell Death Differ 1998; 5: 50-9.
13. Marianneau P, Despres P, Deubel V. Recent knowledge on the pathogenesis of yellow fever and questions for the future. Bull Soc Pathol Exot 1999; 92: 432-4.
14. Oberhaus SM, Dermody TS, Tyler KL. Apoptosis and the cytopathic effects of reovirus. Curr Top Microbiol Immunol 1998; 233: 23-9.
15. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-6.
16. Duarte Dos Santos CN, Frenkiel MP, Courageot MP, Rocha CF, Vazielle-Falcoz MC, Wien MW, et al. Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type-1 virus. Virology 2000; 274: 292-308.
17. Thomson BJ. Viruses and apoptosis. Int J Exp Pathol 2001; 82: 65-76.
18. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810-6.
19. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: Definition, Mechanisms and relevance to disease. American J Med 1999; 107: 489-506.
20. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SClD mice. J Invest Dermatol 2000; 114: 725-30.
21. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A, Muller M, et al. Bcl-2 antisense therapy chemosensetizes human melanoma in SCID mice. Nature Med 1998; 4: 232-4.
22. Olie RA, Hafner C, Kuttel R, Sigrist B, Willers J, Dummer R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002; 118: 505-12.
23. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-23.
24. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH, et al. A nobel bispecific antisense oligonucleotide inhibiting both Bcl-2 and Bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6: 2547-55.
25. Que FG, Phan VA, Phan VH, Celli A, Batts K, Larusso NF, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999; 30:1398-404.
26. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
27. Griffith TS, Lynch DH. TRAIL a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-63.
28. Marsters SA, Pitti RA, Sheridan JP, Ashkenazi A. Control of apoptosis signaling by Apo2 ligand. Recent Prog Horm Res 1999; 54: 225-34.
29. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999; 5: 157-63.
30. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608-13.
31. Cursio R, Gugenheim J, Ricci JE, Crenesse D, Rostagno P, Maulon L, et al. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J 1999; 13: 253-61.
32. Daemen MA, Van 'T Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-49.
33. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, et al. Attenuation of delayed neuronal death mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998; 18: 238-47.
34. Farber A, Connors JP, Friedlander RM, Wagner RJ, Powell RJ, Cronenwett JL. A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice. J Vasc Surg 1999; 30: 752-60.
35. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol 2000; 130: 197-200.
36. Komdratyeva A, Gale K. Intracerebral injection of caspase-3 inhibitor prevents neuronal apoptosis after kainic acid-evoked status epilepticus. Mol Brain Res 2000; 75: 216-24.
37. Li M, Ona VO, Guegan C, Chert M, Jackson-Lewis V, Andrews, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-9.
38. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Med 1999; 5: 97-100.
39. Movsesyan VA, Yakovlev AG, Fan L, Faden AI. Effect of serine protease inhibitor on posttraumatic brain injury and neuronal apoptosis. Exp Neurol 2001; 167: 366-75.
40. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nature Med 1999; 5: 29-33.
41. Dix BR, Edwards SJ, Braithwaite AW. Does the antitumor adenovirus ONYX-O15/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001; 75: 5443-7.